科济药业-B(02171.HK) 宣布,公司自主研发、针对CD19/CD20双标靶的通用型CAR-T细胞治疗候选产品KJ-C2219,已在中国启动一项针对复发陂难治性B细胞非何杰金氏淋巴瘤研究者发起的临床试验。KJ-C2219基于THANK-u Plus平台开发,计划用于治疗血液恶性肿瘤和自体免疫疾病。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-30 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.